Istodax (romidepsin) Patient Assistance Program
Don’t let the high cost of brand HDAC inhibitor disrupt your cutaneous or peripheral T-cell lymphoma treatment. We help eligible patients access Istodax (romidepsin intravenous infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Istodax (romidepsin) is FDA-approved for cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. (Note: The 2021 FDA accelerated approval for peripheral T-cell lymphoma was voluntarily withdrawn after the confirmatory Ro-CHOP trial did not meet its primary endpoint — Istodax is no longer FDA-approved for PTCL as of 2021.) Histone deacetylase (HDAC) inhibitor — epigenetic modulator.
- Without assistance, Istodax costs commonly run approximately $8,000–$12,000 per dose (weekly on days 1, 8, and 15 of each 28-day cycle).
- Through AffordMyPrescriptions, qualifying patients can access Istodax for a flat $69.95 per month.
- Other CTCL therapies: skin-directed therapy (topical corticosteroids, topical chemotherapy nitrogen mustard/Valchlor, topical retinoids/bexarotene Targretin gel, phototherapy PUVA/narrowband UVB, total skin electron beam therapy), systemic therapies (oral bexarotene/Targretin generic, IFN-alpha generic, methotrexate generic, brentuximab vedotin/Adcetris for CD30+, mogamulizumab/Poteligeo, vorinostat/Zolinza generic — another HDAC inhibitor), chemotherapy for advanced disease (gemcitabine generic, pegylated liposomal doxorubicin/Doxil generic, pralatrexate/Folotyn). Other HDAC inhibitor: panobinostat (Farydak — withdrawn in US; outside US for multiple myeloma). For PTCL — multiple regimens including CHOP/CHOP-like backbones, brentuximab vedotin for CD30-expressing, allogeneic SCT for eligible patients.
What is Istodax Prescription Assistance Program?
The Istodax Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Istodax (used for cutaneous T-cell lymphoma after at least one prior systemic therapy) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, hematology or dermatology oncology coordination, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing CTCL.
At AffordMyPrescriptions, our Patient Advocates handle the entire Istodax PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation, follow up with the manufacturer’s program until approval, manage your weekly infusion cycles, and handle annual re-certification — so you never face a gap in your Istodax HDAC inhibitor therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Istodax enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your cutaneous T-cell lymphoma treatment.
Pharmacy Price Comparison
- Without assistance, Istodax costs thousands of dollars per dose at oncology centers. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this CTCL therapy accessible if you qualify. The table below compares typical pricing across major settings to what you'd pay with our Istodax advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Generic bexarotene (alt) | ~$1,500/mo | Generic CTCL alt |
| Hospital oncology | ~$11,500/dose | Save substantially |
| Community oncology | ~$10,000/dose | Save substantially |
| Specialty pharmacy | ~$9,000/dose | Save substantially |
| 340B-eligible institution | ~$8,000/dose | Save substantially |
| Generic vorinostat (alt HDAC) | ~$2,000/mo | Generic oral HDAC alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Istodax — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Istodax Prescription Program?
The Istodax Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Generic vorinostat (oral HDAC inhibitor) and generic bexarotene offer cheaper alternatives for CTCL.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Istodax assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Istodax is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Istodax:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $8,000–$12,000/dose per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Istodax assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Istodax Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Istodax:
Istodax is a cyclic depsipeptide HDAC inhibitor that modulates gene expression through epigenetic mechanisms — inducing tumor cell differentiation, growth arrest, and apoptosis. Approved for CTCL after at least one prior systemic therapy. Note that the PTCL indication was voluntarily withdrawn in 2021 after the Ro-CHOP confirmatory trial did not meet its primary endpoint.
How It Works:
Cutaneous T-cell lymphoma (CTCL) — most commonly mycosis fungoides and Sézary syndrome — is a heterogeneous group of non-Hodgkin lymphomas characterized by T-cell infiltration of the skin. Advanced and refractory CTCL has limited treatment options with modest response rates. Romidepsin inhibits histone deacetylases (HDACs) — increases histone acetylation and chromatin relaxation — altering gene expression patterns that drive tumor cell differentiation, cell cycle arrest, and apoptosis. Independent of T-cell antigen specificity. Effective in some CTCL patients with durable responses, though overall response rates are modest. Other HDAC inhibitor vorinostat (Zolinza, generic) is FDA-approved for CTCL as well.
Form and Use:
Istodax 14 mg/m² IV infusion over 4 hours on days 1, 8, and 15 of each 28-day cycle. Premedication with antiemetics. Continue per protocol — typically until disease progression or unacceptable toxicity. Periodic ECG (QT monitoring, electrolyte management — magnesium and potassium), CBC, comprehensive metabolic panel. Hold for severe cytopenias, infection, significant ECG changes, or other toxicity. Dose modifications per labeling.
Generic Availability:
No generic Istodax. Other CTCL therapies — skin-directed: topical corticosteroids (mid-to-high potency generic), topical chemotherapy (mechlorethamine/nitrogen mustard — Valchlor brand), topical retinoid (bexarotene/Targretin gel), phototherapy (PUVA, narrowband UVB), total skin electron beam therapy (TSEBT). Systemic: oral bexarotene (Targretin — generic now available), interferon-alpha (generic, IFN alfa-2a and 2b), methotrexate (generic), low-dose oral chemotherapy (chlorambucil generic). Targeted: brentuximab vedotin (Adcetris) for CD30+ CTCL per ALCANZA, mogamulizumab (Poteligeo — anti-CCR4 for CTCL after at least one prior systemic therapy). Other HDAC inhibitor: vorinostat (Zolinza — oral, generic now, FDA-approved for CTCL). Chemotherapy for advanced disease: gemcitabine generic, pegylated liposomal doxorubicin (Doxil generic), pralatrexate (Folotyn — DHFR inhibitor for relapsed/refractory PTCL), bendamustine. Allogeneic SCT for eligible advanced/refractory patients. Combination approaches per NCCN guidelines.
Warnings:
QT prolongation and serious arrhythmias (monitor ECG and electrolytes — potassium and magnesium repletion before each dose; avoid additional QT-prolonging drugs), bone marrow suppression (cytopenias — anemia, neutropenia, thrombocytopenia; monitor CBC; hold for severe), infections (bacterial, viral, fungal — including hepatitis B reactivation; consider HBV screening and antiviral prophylaxis if HBV exposure), tumor lysis syndrome (high disease burden — monitor labs, hydrate, consider allopurinol), embryo-fetal toxicity. Other: nausea/vomiting/diarrhea/anorexia (premedicate, supportive care), fatigue, dyspnea, peripheral edema, hyperglycemia, hypotension, dysgeusia. Drug interactions: strong CYP3A4 inhibitors (azoles, clarithromycin, ritonavir, grapefruit) increase romidepsin — caution; strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) reduce efficacy — avoid. QT-prolonging drugs add to QT risk.
FAQ (Frequently Asked Questions)
How much does Istodax cost without insurance?
$8,000–$12,000 per infusion (weekly on days 1, 8, and 15 of each 28-day cycle — typically 3 doses per cycle). Annualized cost can exceed $200,000 depending on response and duration. Generic alternatives (vorinostat, bexarotene) are substantially cheaper.
Is Istodax still FDA-approved for peripheral T-cell lymphoma?
No — the PTCL indication was voluntarily withdrawn by the manufacturer in 2021 after the confirmatory Ro-CHOP trial did not meet its primary endpoint. Istodax remains FDA-approved for cutaneous T-cell lymphoma after at least one prior systemic therapy. PTCL is now treated with other regimens (CHOP/CHOP-like backbones, brentuximab vedotin for CD30+ disease, pralatrexate, allogeneic SCT for eligible patients).
Is Istodax considered chemotherapy?
Istodax is a targeted epigenetic therapy (HDAC inhibitor) — distinct from traditional cytotoxic chemotherapy but does cause myelosuppression and other class-specific toxicities. Different mechanism focused on modulating gene expression through chromatin acetylation.
What is the difference between Istodax and Zolinza (vorinostat)?
Both HDAC inhibitors FDA-approved for CTCL. Vorinostat (Zolinza — generic now available, much cheaper) is oral, taken daily. Istodax (romidepsin) is IV, given weekly. Vorinostat is older, more familiar, less expensive. Both have modest response rates. Choice often by patient preference (oral vs IV), cost, and tolerability.
Why is electrolyte monitoring important on Istodax?
Istodax causes QT prolongation and serious arrhythmia risk — particularly with hypokalemia or hypomagnesemia. Mandatory potassium and magnesium repletion before each dose (target K >3.8, Mg >1.85). Monitor ECG. Avoid additional QT-prolonging drugs (certain antibiotics, antiarrhythmics, antiemetics, antifungals, others).
Take Control of Your Medication Costs
Targeted HDAC inhibitor therapy for cutaneous T-cell lymphoma should not be derailed by cost. Generic vorinostat and bexarotene offer cheaper alternatives. Our Istodax advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Istodax through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.